Statin Use and Development and Progression of Nonalcoholic Fatty Liver Disease Based on Ultrasonography
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgae546 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Baoyu Feng und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences; School of Basic Medicine Pekin…. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Non-alcoholic Fatty Liver Disease, Ultrasonography, Liver. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Beijing Municipal Health Commission Capital Health Development Research Project.
Abstract (Originalsprache)
Context
Nonalcoholic fatty liver disease (NAFLD) has emerged as a public health issue, while no drugs have been specifically approved for treatment.
Objective
This study aimed to examine the association between statin use and NAFLD occurrence, progression, and regression.
Methods
A cohort study was designed based on the Kailuan Study and electronic medical records from the Kailuan General Hospital. Participants aged 18 years with statin indication, including statin and nonstatin users, were enrolled from 2010 to 2017. Propensity score (PS)-matched cohorts were also used.
Results
In the entire cohort, 21 229 non-NAFLD and 22 419 NAFLD patients (including 12 818 mild NAFLD patients) were included in the final analysis. After a median follow-up of about 4 years, the incidence of NAFLD occurrence and progression for statin users was lower than those for nonstatin users (occurrence: 84.7 vs 106.5/1000 person-years; progression: 60.7 vs 75.5/1000 person-years). Compared with nonstatin users, the risk of NAFLD occurrence (hazard ratio [HR]: 0.78; 95% CI, 0.70-0.87) and regression (HR [95% CI]; 0.71 [0.60-0.84]) was decreased in statin users. The significantly negative association was observed only in those with cumulative statin duration of 2 years or more (HR [95% CI] for occurrence 0.56 [0.46-0.69] vs 0.52 [0.30-0.90] for progression) and those with low or moderate atherosclerosis cardiovascular disease (ASCVD) risk (HR [95% CI] for occurrence 0.74 [0.66-0.82] vs 0.68 [0.57-0.80] for progression). No statistically significant correlation was observed between statin use, statin use duration, and NAFLD regression. The PS-matched cohort had similar results.
Conclusion
Taking statin may decrease the risk of NAFLD occurrence and progression in the population with statin indication, suggesting the potential role of statin both in primary and secondary prevention strategies for NAFLD, especially among those with low or moderate ASCVD risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences; School of Basic Medicine Peking Union Medical College, Beijing 100730, China.
- Department of Cardiovascular Medicine, Hengshui People's Hospital, Hengshui, Hebei 53000, China.
- Department of Cardiology, Kailuan General Hospital, Tangshan, Hebei 063000, China.
- School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
ORCID-Profile: Li Wang, Shouling Wu
Förderung
- Beijing Municipal Health Commission Capital Health Development Research Project
Zitieren
APA
Feng, B., Li, F., Lan, Y., Wang, X., Chen, S., Yang, C., Yin, M., Cui, F., Wang, G., Zhou, D., Zhou, Y., Wu, S., Wang, L., & Wu, S. (2025). Statin Use and Development and Progression of Nonalcoholic Fatty Liver Disease Based on Ultrasonography. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae546
Vancouver
Feng B, Li F, Lan Y, Wang X, Chen S, Yang C, et al. Statin Use and Development and Progression of Nonalcoholic Fatty Liver Disease Based on Ultrasonography. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae546
BibTeX
@article{Feng2025,
author = {Feng, Baoyu and Li, Fengde and Lan, Yanqi and Wang, Xiaomo and Chen, Shuohua and Yang, Chenlu and Yin, Meihua and Cui, Feipeng and Wang, Guodong and Zhou, Di and Zhou, Yang and Wu, Shutong and Wang, Li and Wu, Shouling},
title = {Statin Use and Development and Progression of Nonalcoholic Fatty Liver Disease Based on Ultrasonography},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgae546}
}
EUVIMED